Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hyman

Showing results (341-350 of 401) with videos related to

Pageof 41
Sort By:
Cancer Discovery|August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front MutationsAlexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
Gynecologic Oncology|July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trialAna Oaknin, Claire F Friedman, Lynda D Roman, et al.
The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.
JAMA Oncology|November 15, 2019
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer CareAlexander Penson, Niedzica Camacho, Youyun Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian CancerBritta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Pageof 41

Showing results (341-350 of 401) with videos related to

Sort By:
Pageof 41
Cancer Discovery|August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front MutationsAlexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
Gynecologic Oncology|July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trialAna Oaknin, Claire F Friedman, Lynda D Roman, et al.
The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.
JAMA Oncology|November 15, 2019
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer CareAlexander Penson, Niedzica Camacho, Youyun Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian CancerBritta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Pageof 41